Topical treatment is usually reserved for the management of patients with low-risk BCC
Gastrointestinal adverse events were more common with semaglutide 7.2 mg (70.8%) compared with semaglutide 2.4 mg (61.2%) and placebo (42.8%), whereas dysesthesia was more common in the semaglutide 7.2 mg group (22.9%) than in the semaglutide 2.4 mg group (6%) and the placebo group (0.5%), Wharton and colleagues found
Ozempic (semaglutide) stays in your body for a week, keeping appetite signals lower for longer
Big things coming down the pipeline
At the end of the trial, permanent hearing loss occurred twice as often in the placebo group as the magnesium group
As more healthy individuals seek AOM prescriptions for cosmetic or preventive reasons, insurers must consider how to interpret such use in underwriting and build an understanding of the nuanced, evolving interplay among pharmacologic intervention, lifestyle behaviors, and long-term outcomes